Literature DB >> 8157084

Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures.

B Sebök1, B Bonnekoh, J Geisel, G Mahrle.   

Abstract

Oral administration with complex mixtures of fumaric acid derivatives is known to have antipsoriatic efficacy. The present studies aimed to clarify the mode of action and toxicity of the individual compounds. Hyperproliferative HaCaT keratinocytes in monolayer cultures were exposed to fumaric acid, dimethylfumarate, zinc monoethylfumarate, calcium monoethylfumarate and magnesium monoethylfumarate at concentrations between 0.4 microM and 960 microM for 48 h. Cell proliferation was studied by [3H]thymidine incorporation. In addition 14C-labelled amino acid uptake and total protein content were measured. Direct cytotoxicity was determined by the release of cytoplasmic lactate dehydrogenase (LDH) into the culture medium. The corresponding 50% inhibition concentrations (IC50) were calculated for DNA/protein synthesis: 2.3/2.5 microM (dimethylfumarate), 133/145 microM (zinc monoethylfumarate), 215/230 microM (calcium monoethylfumarate), 275/270 microM (magnesium monoethylfumarate), > 960/> 960 microM (fumaric acid). The total protein content was less sensitive. Antiproliferative activity was found for dimethylfumarate and to a lesser degree for calcium monoethylfumarate already at the subtoxic concentrations of 1.3 and 4 microM, respectively. In the case of magnesium monoethylfumarate, zinc monoethylfumarate and fumaric acid there was no such dissociation between their cytotoxic and antiproliferative potential. These data indicate that most of the antipsoriatic potential of fumaric therapies is due to the dimethylfumarate compound.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157084     DOI: 10.1016/0926-6917(94)90083-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  [Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].

Authors:  M Stangel; D Moharregh-Khiabani; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

Review 2.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

3.  Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas.

Authors:  Ali J Ghods; Roberta Glick; David Braun; Douglas Feinstein
Journal:  Surg Neurol Int       Date:  2013-12-24

4.  A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis.

Authors:  Krzysztof Bojanowski; Collins U Ibeji; Parvesh Singh; William R Swindell; Ratan K Chaudhuri
Journal:  JID Innov       Date:  2021-07-08

5.  Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.

Authors:  Simon Gerhardt; Veronika König; Monika Doll; Tsige Hailemariam-Jahn; Igor Hrgovic; Nadja Zöller; Roland Kaufmann; Stefan Kippenberger; Markus Meissner
Journal:  J Inflamm (Lond)       Date:  2015-08-06       Impact factor: 4.981

Review 6.  Fumaric acid esters in the management of psoriasis.

Authors:  Deepak Mw Balak
Journal:  Psoriasis (Auckl)       Date:  2015-01-05

7.  Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors.

Authors:  Zrinka Rajić; Maja Beus; Hana Michnová; Josipa Vlainić; Leentje Persoons; Ivan Kosalec; Josef Jampílek; Dominique Schols; Toma Keser; Branka Zorc
Journal:  Molecules       Date:  2018-07-14       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.